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Abstract
Influenza is an acute viral respiratory disease that affects persons of all ages and is associated with 
millions of medical visits, hundreds of thousands of hospitalizations, and thousands of deaths 
during annual winter epidemics of variable severity in the United States. Elderly persons have the 
highest influenza-associated hospitalization and mortality rates. The primary method of prevention 
is annual vaccination. Early antiviral treatment has the greatest clinical benefit; otherwise, 
management includes adherence to recommended infection prevention and control measures as 
well as supportive care of complications.
Annual epidemics caused by infections with seasonal influenza A or B viruses occur during 
the winter months in temperate climates. Influenza activity may occur year-round in tropical 
and subtropical climates, peaking during cooler or rainy-season months. Influenza usually 
involves self-limited symptoms of the upper respiratory tract, fatigue and myalgia, with or 
without fever. However, young children, elderly persons, pregnant women, and those with 
certain chronic medical conditions are at higher risk for severe disease.
Influenza A viruses are classified into subtypes based on the 2 main surface glycoprotein 
components: hemagglutinin (referred to as “HA” or “H”) and neuraminidase (referred to as 
“NA” or “N”). Influenza viruses bind to receptors on the surface of respiratory epithelial 
cells (primarily of the upper tract) through the HA protein. Most humoral immunity against 
the HA protein, acquired through infection or vaccination, is virus strain-specific.
Antigenic “drift” refers to HA gene mutations causing antigenic changes in the HA protein 
so that antibodies acquired by prior infection or vaccination do not bind to antigenically 
drifted virus strains. Antigenic drift is the unpredictable evolutionary process that drives 
seasonal epidemics and is why year-round influenza surveillance and annual updating of 
vaccine strains are needed. Seasonal influenza viruses currently circulating among humans 
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worldwide include influenza A(H1N1)pdm09 and A(H3N2) viruses and 2main groups (or 
lineages) of influenza B viruses.
Antigenic “shift” refers to human infection with a novel influenza A virus that is 
antigenically and genetically distinct from influenza A viruses circulating in humans. Novel 
influenza A viruses have public health importance because they can cause sporadic human 
infections resulting from exposure to infected animals (usually poultry or pigs) as well as 
pandemics in which most of the population lacks immunity to the novel virus strain.
Prevention
Who is at greatest risk for complications and hospitalization?
High-risk persons include young children younger than 5 years and particularly those under 
2; adults aged 65 years and older; pregnant women; residents of nursing homes and other 
long-term care facilities; American Indians and Alaska Natives; persons of any age with 
certain underlying medical conditions, such as chronic lung disease, cardiac disease (but not 
isolated hypertension), neurologic and neurodevelopmental conditions, hematologic 
disorders, kidney or liver disorders, metabolic diseases, or immunosuppression; persons 
younger than 19 years receiving long-term aspirin therapy; and Extremely obese persons 
(body mass index ≥40 kg/m2) (see the Box) (1).
In the United States, persons aged 65 years and older hav the highest rate of influenza 
associated hospitalization, followed by those aged 50–64 years and then young children. 
Mortality rates are highest in persons aged 65 years and older.
Who should receive vaccination, and when should it be given?
All persons aged 6 months and older in the United States should be vaccinated annually, 
ideally before influenza activity begins in the community and by the end of October, if 
possible (1). Recent studies have reported evidence of waning vaccine effectiveness during 
the influenza season (2,3), suggesting that summertime vaccination might be too early; 
however, more studies are needed. Clinicians need to keep abreast of possible changes in 
recommended timing of influenza vaccination. The Centers for Disease Control and 
Prevention (CDC) maintains updated recommendations on its Web site (see Tool Kit for 
links).
Previously unvaccinated children aged 6 months up to 9 years should receive 2 doses at least 
4 weeks apart in the first year of vaccination; for all other groups, revaccination is not 
recommended during influenza season. Although vaccination is not approved for infants 
younger than 6 months, strategies to prevent influenza in this group include vaccination of 
pregnant women, household contacts aged 6 months and older, and caregivers. Randomized 
controlled studies have established that maternal vaccination can prevent influenza in infants 
(through transplacentally transferred antibodies) up to 6 months after birth (4–6).
Although influenza activity in the United States usually peaks during December to March, it 
varies widely and may continue into April or May in some communities. Influenza B viruses 
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often peak later and circulate longer than influenza A viruses. As long as influenza viruses 
are circulating in a community, influenza vaccination can be beneficial.
Persons with significant febrile illness generally should not be vaccinated, based on clinical 
judgment; minor acute illness without significant fever is not a contraindication.
If difficulties in vaccine production or distribution result in shortages or delays, priority 
should be given to persons at high risk for severe disease or complications and to their close 
contacts, including health care workers (1). The CDC has provided recommendations on its 
Web site for prioritizing influenza vaccination under these circumstances.
How effective is the vaccine?
Effectiveness of influenza vaccine varies from season to season and is influenced by such 
factors as age, baseline health, and immune function as well as the degree of antigenic match 
between vaccine strains and circulating influenza viruses. If vaccine antigens and virus 
strains are well-matched, effectiveness is moderate; however, it is lower during seasons 
when they are mismatched. Effectiveness can also vary by virus type and influenza A virus 
subtype. In a systematic review and meta-analysis of 10 randomized controlled trials, 
efficacy of the trivalent inactivated vaccine was found in 8 of 12 seasons, with a pooled 
efficacy of 59% (95% CI, 51%−67%) in adults aged 18–65 years (7).
A recent systematic review and meta-analysis of studies of vaccine effectiveness in 
outpatients reported that the overall pooled effectiveness was 33% for A(H3N2), 
54% for influenza B, and 61% for A(H1N1)pdm09. Effectiveness was 33% when 
the H3N2 vaccine antigen was well-matched to the circulating A(H3N2) viruses but 
only 23% when antigenic drift was present (8). For adults older than 60 years, 
pooled effectiveness was 24% for A(H3N2), 62% for A(H1N1)pdm09, and 63% for 
influenza B.
Vaccination is moderately effective in preventing hospitalization (9–12) and influenza-
associated death in children (13) but is generally less effective in elderly than in nonelderly 
persons. However, few clinical trials have focused on elderly persons, and selection bias may 
lead to vaccination of healthier persons.
A meta-analysis of individual-participant data involving case-control studies of 
nearly 5000 community-dwelling older adults worldwide re- ported that vaccination 
was moderately effective (adjusted effectiveness was 44.4% during well- matched 
seasons and 20% during mismatched seasons) in preventing laboratory-confirmed 
influenza (14). This study also found that vaccination was effective in older adults 
with cardiovascular disease (adjusted effectiveness, 31%) or respiratory disease 
(adjusted effectiveness, 31%) and those aged 75 years or younger (adjusted 
effectiveness, 33%).
Recently, data have become available for vaccines with higher antigen content than standard-
dose (SD) vaccine. One randomized controlled trial that included more than 8500 adults 
aged 50 years or older reported that a recombinant vaccine with 3 times the HA antigen 
content for each strain provided greater protection against laboratory-confirmed influenza 
than SD vaccine (15). A cluster randomized trial of high-dose (HD) inactivated influenza 
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vaccine containing 4 times the antigen content for each strain versus SD inactivated 
influenza vaccine in elderly nursing home residents reported that HD vaccine significantly 
reduced respiratory-related hospitalizations compared with SD vaccine (16).
What vaccines are available?
The composition of influenza vaccines is updated annually. A wide variety of vaccines are 
approved and available in the United States (Table 1), including inactivated trivalent (IIV3) 
or quadrivalent (IIV4) vaccines; the vaccine given depends on the age of the recipient (1). 
Vaccines typically become available in the late summer and expire on 30 June after the end 
of each influenza season.
IIV3 vaccines contain 2 influenza A virus antigens-an A(H3N2) and an A(H1N1)pdm09 
virus-and 1 influenza B virus antigen. IIV4 vaccines contain A(H3N2) and A(H1N1)pdm09 
virus antigens and 2 influenza B virus antigens-1 each of the 2 main circulating lineages (B/
Yamagata and B/Victoria). Most IIV3 and IIV4 vaccines are given by intramuscular 
injection; however, an intradermal IIV4s vaccine is available for adults aged 18–64 years.
Most viruses are grown in embry-onated chicken eggs and then inactivated; however, 2 
approved vaccines use antigens that are not grown in eggs, including 1 quadrivalent vaccine 
comprising viruses that are grown in tissue cell culture (ccIIV4) and then inactivated. One 
vaccine approved for adults that is not based on cultured viruses is a recombinant HA 
vaccine (RIV3 or RIV4) produced in insect cells.
For persons aged 65 years and older, SD vaccines have decreased immunogenicity and 
effectiveness. Two vaccines are now available that may improve protection in this group: an 
adjuvanted IIV, and an HD IIV with 4 times the antigen concentration of SD vaccines.
Live attenuated influenza virus vaccine is approved by the U.S. Food and Drug 
Administration for intranasal administration for nonpregnant healthy persons (without 
underlying medical conditions) aged 2–49 years. However, due to poor effectiveness over 
multiple seasons, particularly for the influenza A(H1N1)pdm09 virus strain, the Advisory 
Committee on Immunization Practices and the CDC recommended that this vaccine not be 
used for the 2016–2017 or 2017–2018 seasons (1).
What adverse effects are associated with vaccination?
The most common adverse effect from injectable inactivated influenza vaccines is soreness 
at the injection site for about 2 days (1). Pain, low-grade fever, myalgia, headache, and 
fatigue are less common and may last 1–2 days. Erythema, induration, swelling, and pruritus 
may be more common with intradermal vaccines. Studies of influenza vaccination in 
pregnant women have not identified any significant adverse pregnancy or fetal outcomes 
(17–21).
Whether influenza vaccination increases the risk for Guillain-Barre syndrome (GBS) is 
unknown. One systematic review and meta-analysis of observational studies reported a slight 
association between influenza vaccination and GBS (22). In general, persons who previously 
had GBS within 6 weeks after being vaccinated and are not at risk for severe influenza 
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complications should not be vaccinated. For persons who are more likely to have influenza 
complications, the small risk for GBS is probably outweighed by the benefit of vaccination, 
which can also reduce the small risk for GBS that can be triggered by influenza virus 
infection (23, 24). For non-pregnant adults, some studies have reported a low risk for GBS 
(approximately 1 case per 1 million vaccinated persons) (1).
How should clinicians approach vaccination in persons with severe allergies?
Anaphylaxis after influenza vaccination is rare. Although most influenza vaccines are grown 
in embryonated chicken eggs (except RIV3, RIV4, and ccIIV4 vaccines), severe reactions-
even in persons with egg allergies-are uncommon. Influenza vaccine can be given to persons 
with a history of egg allergy who have had only hives after exposure to eggs. Persons who 
report other allergic symptoms, such as angioedema, respiratory distress, lightheadedness, or 
recurrent vomiting, or those who required epinephrine or other emergency medical 
intervention for anaphylaxis can still be vaccinated, but it should be done in an inpatient or 
outpatient medical setting supervised by a health care provider who can recognize and 
manage severe allergic reactions (1). However, anyone who has had a more severe allergic 
reaction should not be vaccinated.
What is the role of behavioral strategies to prevent transmission?
Immunocompetent persons who are symptomatic from uncomplicated influenza virus 
infection can shed viruses from the upper respiratory tract for approximately 4–7 days, 
although shedding and transmissibility generally decrease substantially after 3 days. 
Influenza viruses are believed to be transmitted primarily by large and small particle droplets 
that are expelled by coughing or sneezing by an infected person to susceptible close 
contacts. Contact transmission has been suggested indirectly through hand hygiene studies. 
The role of asymptomatically infected or presymptomatic persons in transmitting the viruses 
is unknown, but this is believed to be uncommon.
A systematic review and meta-analysis examined randomized clinical trials 
studying the efficacy of hand hygiene (with or with-out facemasks) in reducing 
influenza virus transmission in community settings (house-holds). It reported that 
hand hygiene combined with facemasks resulted in a statistically significant 
reduction in laboratory-confirmed transmission (relative risk, 0.73 [CI, 0.53–0.99]; 
P = 0.05), but hand hygiene alone did not (25). Another review concluded that 
evidence of the efficacy of nonpharmaceutical interventions, such as facemasks and 
hand hygiene, to reduce transmission was lacking, with most studies being 
significantly flawed (26).
Community nonpharmaceutical interventions, such as school closures, have been 
implemented to control seasonal and pandemic influenza; effectiveness has varied (27).
What is the role of antiviral agents in prevention?
The neuraminidase inhibitors oral oseltamivir and inhaled zanamivir are approved for 
antiviral treatment and chemoprophylaxis of influenza. Antiviral chemoprophylaxis (before 
or after exposure) of individuals or in households has moderate to high effectiveness for 
influenza prevention (28) but is not routinely recommended. Antiviral chemoprophylaxis 
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can be considered for persons in whom vaccination is contraindicated or who are not 
expected to benefit, such as severely immunosuppressed patients.
Antiviral chemoprophylaxis is an important component of a bundle of interventions to 
control institutional influenza outbreaks, and oseltamivir chemoprophylaxis has been shown 
to be effective in controlling established outbreaks in nursing homes (29–31). When an 
institutional outbreak is recognized, some exposed residents or patients may already be 
incubating influenza virus when antiviral chemoprophylaxis is implemented. Therefore, 
consideration can be given to twice-daily (i.e., treatment dosing) versus once-daily 
chemoprophylaxis dosing in long-term care facilities or health care facilities, including in 
immunosuppressed persons (32, 33).
A cluster randomized trial compared oseltamivir treatment of symptomatic persons 
with oseltamivir chemoprophylaxis for elderly long-term care residents over 3 
seasons. It found that postexposure chemoprophylaxis reduced the influenza attack 
rate among residents compared with treating symptomatic persons (34). One 
multicountry randomized controlled trial of oseltamivir chemoprophylaxis versus 
placebo for 6 weeks in vaccinated nursing home residents reported high efficacy in 
preventing outbreaks (35).
During an institutional outbreak, unvaccinated staff members and residents should receive 
influenza vaccine if it is available. In nursing homes, the potential for high-intensity virus 
exposure and possible suboptimal immune response to vaccine by debilitated residents 
suggests that all residents, regardless of previous vaccination, should receive 
chemoprophylaxis in an outbreak. Antiviral medications should be continued for at least 2 
weeks, and then for 1 week longer than the duration of the outbreak.
Antiviral chemoprophylaxis may also be considered for high-risk persons and close contacts 
(including health care workers) when vaccine is unavailable or contraindicated, when a 
major difference exists between the predominant virus antigens and the vaccine strains such 
that effectiveness is expected to be very low, or when severe immunosuppression makes 
response to the vaccine unlikely.
What measures should clinicians take to prevent influenza among patients and staff in 
health care institutions?
All health care personnel should be vaccinated annually unless it is contraindicated or the 
vaccine is unavailable. In outpatient settings, persons with suspected or confirmed influenza 
should be encouraged to adhere to respiratory hygiene, cough etiquette (use facemasks or 
tissues to cover the nose and mouth when coughing, and dispose of contaminated materials), 
and hand hygiene recommendations. For inpatient settings, patients with suspected or 
confirmed influenza should be isolated or cohorted (co-located) if isolation is not possible. 
Standard and droplet precautions are recommended, and for aerosol-generating procedures a 
fit-tested N95 respirator or respirator equivalent is recommended (36).
The use of standing orders, which allow trained health care professionals other than 
physicians to identify and vaccinate high-risk patients, improves influenza vaccine coverage 
of hospitalized patients at discharge and nursing home residents, especially if structured in 
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an “opt-out” format. Likewise, providing free vaccination at convenient times and places 
may increase coverage among hospital and nursing home staff.
During outbreaks, infection prevention and control measures, such as limiting visitors, using 
droplet precautions, isolating or cohorting symptomatic patients, and performing active daily 
surveillance for new cases, should also be implemented.
Diagnosis
What signs and symptoms should prompt clinicians to suspect influenza?
Signs and symptoms of uncomplicated influenza frequently overlap with those of other 
respiratory viral infections, but abrupt onset of fever, especially high fever or feverishness, 
and cough can help in differentiation, especially if influenza activity is present in the 
community (37–39). Although weakness, myalgia, sore throat, nausea, rhinorrhea, and 
headache are common in patients with influenza, they occur with similar frequency in other 
viral illnesses. Not all persons with influenza manifest fever, including immunosuppressed 
and elderly persons (40). Young children with respiratory symptoms may have diarrhea, and 
adults with respiratory symptoms may have vomiting. The presence of crackles or decreased 
breath sounds on chest examination may suggest such pulmonary complications as viral 
pneumonia, secondary bacterial pneumonia, or heart failure.
When should clinicians suspect novel influenza A virus infection?
The key to diagnosing novel influenza A virus infection is to elicit a history of recent 
exposure to poultry or pigs where novel influenza A viruses are circulating among animal 
hosts, or exposure to an ill person with novel influenza A virus infection. Disease severity in 
infected animals does not necessarily correlate with severity in infected humans.
Similar to seasonal influenza, a wide clinical spectrum of human infection with novel 
influenza A viruses has been reported, including asymptomatic infection, conjunctivitis only, 
upper respiratory tract illness, pneumonia, encephalopathy and encephalitis, and multi organ 
failure with fatal outcomes (41, 42). Therefore, novel influenza A virus infection cannot be 
distinguished from seasonal influenza A virus infection by clinical findings or by 
commercially available tests and must be diagnosed by specific influenza molecular assays 
at public health laboratories (43, 44).
When should clinicians test to confirm a clinical diagnosis?
Influenza testing (Table 2) is not needed to confirm the clinical diagnosis or to decide 
whether to prescribe antiviral medications to a patient when influenza viruses are circulating 
in the community (45). Testing should be considered when the results will influence 
individual clinical management decisions. In an institutional (long-term care facility or 
hospital ward) outbreak of respiratory illness, diagnostic testing can help establish influenza 
as the cause, supporting prompt implementation of prevention and control measures.
Respiratory specimens should be collected as close to illness onset as possible. In critically 
ill patients, the diagnosis may be missed if only upper respiratory tract specimens are tested, 
even with molecular assays. Viral replication may be prolonged in the lower respiratory 
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tract, and testing endotracheal aspirate or bronchoalveolar fluid specimens may thus yield a 
diagnosis of influenza (46, 47).
Clinicians must understand the limitations of influenza tests and interpretation of their 
results (48, 49). Sensitivity of virus detection is generally higher in children than in adults, 
higher with nasopharyngeal or nasal specimens than with throat samples, and higher during 
the first few days of illness. The positive predictive value of the tests is highest during high 
influenza activity, and the negative predictive value is highest during low influenza activity 
or outside the season. Clinicians who are evaluating travelers returning from overseas should 
understand that during periods of low influenza activity in the United States, activity may be 
high in temperate climates in the Southern Hemisphere and that influenza activity occurs 
year-round in countries with tropical and subtropical climates.
Different influenza tests (Table 2) are available for respiratory specimens (50). The most 
accurate tests with the highest sensitivity and specificity are molecular assays, including 
reverse transcription polymerase chain reaction (RT-PcR) assays (51). Most molecular 
assays take about 60–80 minutes to produce results, but some require only 20 minutes, with 
moderately high sensitivity compared with other molecular assays. Antigen detection assays, 
including rapid influenza tests that yield results in approximately 10 minutes, and 
immunofluorescence assays have low to moderate sensitivity in detecting influenza viruses 
in respiratory specimens; therefore, false-negative results with these tests are common 
during peak influenza activity. For hospitalized patients with suspected influenza, molecular 
assays are recommended (51). Isolation and implementation of infection prevention and 
control measures and initiation of empirical antiviral treatment should not be delayed 
pending test results.
Viral culture is important for influenza virus surveillance and public health but does not 
yield timely results to inform clinical management. Serologic testing should not be routinely 
done to diagnose influenza because of the need for collection of acute and convalescent 
serum specimens. Serologic testing of a single serum specimen is not interpretable and has 
no role in diagnosis or clinical management of seasonal influenza.
Diagnosing influenza through testing can preclude unnecessary antibiotic use and additional 
laboratory tests and facilitate antiviral use and patient isolation (52, 53).
What complications are associated with influenza?
Complications vary by age, immune function, and underlying medical conditions. Influenza 
may exacerbate underlying chronic disease (e.g., chronic obstructive pulmonary disease or 
heart failure). Persons with chronic obstructive pulmonary disease or severe 
immunosuppression and elderly persons may be at greater risk for pneumonia with 
influenza.
Other complications include otitis media, bronchiolitis, and croup in young children and 
sinusitis in older children and adults. Bronchospasm, bronchitis, and pneumonia can occur at 
any age. Pneumonia can be directly due to influenza virus or bacterial co-infection; can 
occur with or without pleural effusion; and can progress rapidly to respiratory failure, acute 
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respiratory distress syndrome, and refractory hypoxemia. Cardiac complications include 
myocarditis, pericarditis, heart failure, and myocardial infarction. A wide range of 
neurologic complications includes seizures, transient encephalopathy to acute necrotizing 
encephalopathy and encephalitis, cerebrovascular accident, acute disseminated 
encephalomyelitis, and GBS. Musculoskeletal complications include severe myositis and 
rhabdomyolysis. Levels of hepatic aminotransferases can be elevated, but liver failure is rare. 
Bacterial co-infection can result in pneumonia, bacteremia, and meningitis. Acute kidney 
injury and renal failure can occur in some patients. Critically ill patients may manifest with 
multi organ failure (respiratory and renal), shock, and sepsis.
When should clinicians suspect bacterial co-infection in patients believed to have 
influenza?
Clinicians should consider bacterial co-infection in patients with suspected or confirmed 
influenza who present with severe disease, remain ill, worsen, or have acute onset of high 
fever or respiratory distress after initial improvement. Adults with uncomplicated influenza 
typically have fever and symptoms for about 3 days, by which time most show signs of 
improvement. Although it may take 10–14 days for complete recovery, and longer in older 
adults, lack of improvement or worsening symptoms suggest either a complication or an 
alternative diagnosis.
The bacteria most commonly implicated in community-acquired pneumonia with influenza 
are Streptococcus pneumoniae, Staphylococcus aureus (both methicillin-sensitive and 
methicillin-resistant), and group A Streptococcus (54). An association between bacterial 
meningitis due to Neisseria meningitides and influenza has been reported (55).
Patients who remain febrile for more than 3–5 days or who develop fever, worsening 
symptoms, or progressive disease require evaluation. Symptoms and clinical findings should 
guide blood tests, cultures, and imaging studies. Consultation with an infectious disease 
specialist should be considered, especially if the patient is severely ill or immunosuppressed. 
The differential diagnosis should be expanded to include bacterial infection in patients 
whose condition deteriorates rapidly, and work-up and treatment should be adjusted 
accordingly.
Treatment
What is the role of hydration and antipyretics?
Hydration is important to replace insensible water loss that occurs with fever. Antipyretics, 
such as acetaminophen or ibuprofen, can help reduce fever and prevent further insensible 
water loss. Reduction of fever can prevent other consequences of increased metabolic rate, 
such as tachycardia, and relieve such symptoms as chills and myalgia. There is no 
convincing evidence that antipyretic therapy prolongs or shortens the disease course. Aspirin 
and aspirin-containing medication must be avoided in patients with suspected or confirmed 
influenza, particularly in adolescents and children, because of the association between 
salicylates and Reye syndrome in persons with influenza (56, 57).
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What is the role of antiviral medications?
Neuraminidase inhibitors (oral oseltamivir, inhaled zanamivir, and intravenous peramivir) 
are recommended antiviral treatments for influenza. Treatment duration in outpatients is 
typically 5 days. These drugs have activity against influenza A and B viruses but differ by 
approved age groups, routes of administration, and adverse effects (Table 3). Dual 
neuraminidase inhibitor treatment is not recommended because of reports of antagonism 
with this therapy compared with monotherapy (58). Inhaled zanamivir is generally not 
recommended for hospitalized patients. In critically ill patients, oseltamivir can be given 
enterally by orogastric or nasogastric administration. The adamantane drugs (amantadine 
and rimantadine) have no activity against influenza B viruses and are not recommended for 
treatment of influenza A virus infection because currently circulating influenza A viruses 
(A[H1N1]pdm09 and A[H3N2]) are resistant to these drugs.
Randomized placebo-controlled trials of antiviral treatment of influenza in hospitalized 
patients are lacking. However, the CDC recommends prescribing neuraminidase inhibitor 
antiviral treatment to all hospitalized patients with confirmed or suspected influenza as soon 
as possible, without waiting for test results. Abundant observational data from hospitalized 
patients with influenza indicate that the greatest clinical benefit is achieved when antiviral 
treatment is started as close to illness onset as possible, although benefit is still possible 
when it is started 48 or more hours after onset compared with no treatment (59). For 
outpatients with suspected or confirmed influenza in a group at high risk for complications, 
and for those with progressive disease who do not require hospitalization, antiviral treatment 
is recommended even if more than 2 days have passed since illness onset. For otherwise 
healthy persons with suspected or confirmed uncomplicated influenza who are not at high 
risk for complications and who present within 2 days of illness onset, clinical judgment can 
be used to decide whether to prescribe antiviral treatment.
Randomized clinical trials in out-patients with uncomplicated influenza have established the 
efficacy of early (≤2 days after illness onset) neuraminidase inhibitor treatment to reduce the 
duration of illness by approximately 0.6–1 day (60, 61). A meta-analysis of randomized 
controlled trials of oseltamivir treatment versus placebo in adult outpatients reported that 
oseltamivir significantly reduced the risk for lower respiratory tract complications requiring 
antibiotic treatment as well as the risk for hospitalization for any cause but increased the risk 
for nausea and vomiting (60).
A meta-analysis of individual observational data from 3376 patients of all ages at 
high risk for hospitalization with suspected or confirmed influenza A(H1N1)pdm09 
virus infection reported that outpatient neuraminidase inhibitor treatment was 
associated with a significantly reduced likelihood of hospitalization compared with 
no antiviral treatment (62).
Although oseltamivir and zanamivir are pregnancy category C drugs, the CDC advises that 
pregnancy should not be considered a contraindication. Oseltamivir is recommended over 
inhaled zanamivir because of concerns about lower lung volumes in pregnancy causing 
reduced zanamivir distribution and potential bronchospasm (63). Cohort studies have 
concluded that oseltamivir treatment is safe and that there is no evidence that treatment of 
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pregnant women with this drug is associated with any adverse pregnancy or birth outcomes 
(64, 65).
An individual-patient-level meta-analysis (78 observational studies with >29 000 
hospitalized patients with suspected or laboratory-confirmed influenza 
A[H1N1]pdm09 virus infection) reported that neuraminidase inhibitor treatment of 
adults was associated with reduced risk for death compared with no antiviral 
treatment. Treatment initiation within 2 days of illness onset was associated with 
reduced risk for death compared with starting treatment more than 2 days after 
onset (59). Similarly, when the analysis was limited to pregnant women, early 
initiation was associated with reduced risk for death compared with no treatment or 
later initiation of treatment, and neuraminidase inhibitor treatment at any time after 
illness onset was associated with reduced risk for death versus no treatment.
When should patients be hospitalized?
Hospitalization should be considered for patients with significant dehydration and severely 
ill persons who have complications of suspected or laboratory-confirmed illness, especially 
those with respiratory distress, hypoxemia, impaired cardiopulmonary function, or altered 
mental status. Likewise, patients who have an uncertain clinical course or are frail at 
baseline might require admission for close observation.
When should clinicians consult an infectious disease specialist or public health authority?
Diagnostic consultation may be useful in seriously ill patients in whom influenza is 
suspected but unproven, in patients with atypical presentations, when severe complications 
are suspected, and when the differential diagnosis is broad (e.g., immunosuppressed patients 
with pneumonia).
Infectious disease specialists can guide the use of antiviral agents and help determine the 
need for antimicrobial agents and should also be consulted if antiviral resistance is 
suspected. They can help manage severely immunosuppressed patients with influenza and 
guide use of investigational antivirals, either through a clinical trial or for compassionate 
use. Pulmonary or critical care specialists can help with procedures for maintaining 
oxygenation in critically ill patients and obtaining specimens for testing.
Public health authorities should be consulted if novel influenza A virus infection is 
suspected based on clinical presentation, reported exposure to animals or to a patient with 
such infection, and pertinent travel history. State health departments can use RT-PCR to test 
specifically for seasonal influenza A as well as novel influenza A viruses originating from 
animals, with confirmation at the CDC. Public health authorities are responsible for 
monitoring disease outbreaks, determining the source, evaluating possible human-to-human 
transmission, and instituting measures to limit further transmission in close contacts. 
Clinicians should view CDC recommendations on specimen collection and testing, antiviral 
treatment and chemoprophylaxis, infection prevention and control, and monitoring of close 
contacts.
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Practice Improvement
What measures do stakeholders use to measure the quality of care?
The Centers for Medicare & Medicaid Services (CMS) requires participating nursing homes 
to offer influenza vaccine to all residents. For preventive care and screening, the CMS 
includes influenza vaccination screening of patients aged 6 months or older as a quality 
measure in its Merit-Based Incentive Payment System. It also requires acute care hospitals, 
ambulatory surgical centers, outpatient dialysis facilities, inpatient rehabilitation facilities, 
inpatient psychiatric facilities, and long-term acute care facilities to report data on influenza 
vaccination among health care personnel to the CDC (66).
The Joint Commission requires accredited organizations to establish an annual influenza 
vaccination program for all employees, including licensed independent practitioners and 
nonclinical staff, and to measure the screening of patients admitted to acute care hospitals 
during the influenza season (October through March) for vaccination before discharge, if 
indicated (67,68).
What do professional organizations recommend with regard to prevention and treatment?
The recommendations of most professional medical organizations are consistent with CDC 
recommendations. The CDC publishes the annual recommendations of the Advisory 
Committee on Immunization Practices for use of approved influenza vaccines in the United 
States and also provides updated antiviral recommendations for influenza on its Web site. 
The Infectious Diseases Society of America publishes recommendations for influenza 
testing and antiviral treatment. The recommendations listed in this article reflect those 
guidelines.
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Appendix
In the Clinic Tool Kit
Influenza
Clinical Guidelines—www.idsociety.org/Guidelines/Patient_Care/
IDSA_Practice_Guidelines/Infections_By_Organism-28143/Viruses/Influenza
Guidelines from the Infectious Diseases Society of America.
www.idsociety.org/Guidelines/Patient_Care/IDSA_Practice_Guidelines/
Vaccination_of_the_Immunocompromised_Host
Guidelines from the Infectious Diseases Society of America for immunization in 
immunosuppressed patients.
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www.who.int/csr/resources/publications/swineflu/
h1n1_guidelines_pharmaceutical_mngt.pdf
Guidelines from the World Health Organization for pandemic influenza.
Patient Information—www.cdc.gov/flu/freeresources/print.htm
Information for patients and health care workers from the Centers for Disease Control and 
Prevention (CDC) (available in English and Spanish).
www.immunize.org/catg.d/p4208.pdf
Information for parents and patients.
www.acog.org/Patients/FAQs/The-Flu-Vaccine-and-Pregnancy
Information for pregnant women on influenza and influenza vaccination.
Information for Health Professionals From the CDC—www.cdc.gov/flu/index.htm
www.cdc.gov/flu/weekly/fluactivitysurv.htm
Surveillance.
www.cdc.gov/flu/professionals/acip/index.htm
Vaccine recommendations.
www.cdc.gov/flu/professionals/diagnosis/index.htm
Testing information, including information on interpretation of test results.
www.cdc.gov/flu/professionals/antivirals/index.htm
Antiviral information and current recommendations.
www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm
Summary on antivirals.
www.cdc.gov/flu/avianflu/index.htm
Novel influenza A virus infections.
WHAT YOU SHOULD KNOW ABOUT INFLUENZA
What Is Influenza?
Influenza is a virus that makes you feel sick and can cause serious health problems. It’s 
often called “the flu.” The flu is spread when an infected person coughs or sneezes close to 
you. It is usually spread during the winter or cooler months but can be spread all year long.
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What Are the Signs and Symptoms?
• High fever
• Feeling tired and weak
• Feeling sore and achy
• Sore throat
• Cough
• Headache
How Is It Diagnosed?
Your doctor will ask you questions about your symptoms. This is generally all the 
information your doctor needs to diagnose the flu; however, in some cases, you may need a 
physical examination or tests.
Can It Cause Health Complications?
Usually the flu is not serious, and you will start to feel better after 3 to 5 days and fully 
recover within 1 to 2 weeks. However, in some persons it can cause serious health 
complications resulting in a hospital stay or even death. You are at higher risk for flu 
complications if you are:
• Aged 65 years and older
• Pregnant
• Living in a nursing home
• American Indian or Alaska Native
• Obese
You are also at higher risk if you have certain health problems. These include:
• Lung disease
• Heart disease
• Weakened immune system
How Is It Treated?
Your doctor may prescribe antiviral treatment for the flu. All of the following are ways to 
feel better:
• Rest.
• Stay hydrated by drinking lots of clear fluids.
• Use over-the-counter medicines, like acetaminophen or ibuprofen, to help bring 
your fever down. These medicines can also help aches.
• Avoid taking aspirin.
Uyeki Page 14
Ann Intern Med. Author manuscript; available in PMC 2019 August 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
If you are at risk for complications, your doctor may prescribe medicines called antivirals 
that help your body fight the flu virus. They may work best if they are started within 2 days 
of getting flu symptoms, but may still be helpful if they are started after that time.
Should I Get a Flu Shot?
Everyone 6 months and older should get a flu shot, preferably by the end of October each 
year. There are different types of vaccines available. Ask your health care provider which is 
best for you. If you have severe allergies to eggs, you may get a flu shot but you should be 
watched by a health care provider afterwards to make sure you do not develop a bad 
reaction. You should not get the flu shot if you ever had a serious allergic reaction to it in the 
past.
How Can I Prevent Spreading the Flu?
• If you think you have the flu, stay home from work or school.
• Use a facemask or tissue to cover your mouth and nose when coughing.
• Wash your hands often.
• Stay away from others until your fever is gone and your cough is better.
For More Information
Centers for Disease Control and Prevention
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https://www.cdc.gov/flu/index.htm
World Health Organization
www.who.int/mediacentre/factsheets/fs211/en/
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Groups at Greatest Risk for Influenza-Related Complications and 
Hospitalization
Children aged <5 y, especially <2 y
Adults aged ≥65 y
Residents of nursing homes and long-term care facilities
Pregnant women
Persons aged <19 y receiving long-term aspirin therapy
American Indians and Alaska Natives
Persons of any age with the following chronic medical conditions:
• Pulmonary disease (including asthma, chronic obstructive pulmonary disease, 
cystic fibrosis)
• Cardiac disease (excluding isolated hypertension)
• Neurologic and neurodevelopmental conditions
• Hematologic disorders
• Endocrine disorders
• Renal disorders
• Hepatic disease
• Metabolic disease
• Immunosuppression (due to disease or medication)
• Extreme obesity (body mass index ≥40 kg/m2)
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CLINICAL BOTTOM LINE
Prevention...
Annual influenza vaccination is recommended for all persons aged 6 months and older in 
the United States, including health care personnel. Vaccination is moderately effective in 
preventing influenza.Recent studies have suggested that it may also help to reduce the 
risk for some complications associated with influenza, including hospitalization and 
death. Antiviral chemoprophylaxis can be an adjunct to influenza vaccination under some 
circumstances.
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CLINICAL BOTTOM LINE
Diagnosis...
Clinical diagnosis of uncomplicated influenza based on abrupt onset of fever, cough, and 
myalgia is usually reliable when influenza activity is present in the community. 
Complications of influenza should be considered in high-risk persons, including those 
with certain chronic comorbidities, young children, pregnant women, elderly persons, 
extremely obese persons, residents of long-term care facilities, and American Indians and 
Alaska Natives. In outpatients, influenza testing can be considered if the results will 
change clinical management decisions. Molecular assays with high sensitivity and 
specificity can help guide management decisions in individual patients, including those 
with severe disease. Clinical decisions and management, especially related to initiation of 
antiviral treatment and implementation of infection prevention and control measures, 
should not be delayed pending test results. Proper interpretation of test results, especially 
negative results, is important to successful clinical management.
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CLINICAL BOTTOM LINE
Treatment...
The mainstay of influenza treatment is early initiation of antiviral agents in outpatients 
with suspected or confirmed influenza who are at high risk for complications or have 
progressive disease and in hospitalized patients with suspected or confirmed influenza. 
Supportive care of complications should be provided, with prompt implementation of 
recommended infection prevention and control measures.
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en
t d
at
a 
o
n
 e
ffi
ca
cy
 fo
r h
os
pi
ta
liz
ed
 p
at
ie
nt
s
*
U
pd
at
ed
 in
fo
rm
at
io
n 
an
d 
gu
id
an
ce
 o
n 
us
e 
of
 a
nt
iv
ira
l m
ed
ic
at
io
ns
 fo
r t
re
at
m
en
t a
nd
 c
he
m
op
ro
ph
yl
ax
is 
of
 in
flu
en
za
 a
re
 av
ai
la
bl
e 
on
 th
e 
W
eb
 si
te
 o
f t
he
 C
en
te
rs
 fo
r D
ise
as
e 
Co
nt
ro
l a
nd
 P
re
v
en
tio
n 
(w
w
w
.
cd
c.
go
v
/fl
u/
pr
of
es
sio
na
ls/
an
tiv
ira
ls/
in
de
x
.h
tm
).
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